Cargando…
Injection site reaction induced by liraglutide use in a female patient with obesity
INTRODUCTION: Glucagon-like peptide-1 agonists (GLP-1 agonists) are one of the top treatment options in obesity and/or type 2 diabetes (T2D) according to the guidelines. It is well tolerated in patients with cardiovascular disease or chronic kidney disease. Allergic symptoms such as rash and pruritu...
Autores principales: | Ayhan, Ihsan, Topaloğlu, Ömercan, Tekin, Sakin, Bayraktaroğlu, Taner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653154/ http://dx.doi.org/10.1210/jcemcr/luac014.039 |
Ejemplares similares
-
Successful use of liraglutide in a female patient with type 1 Gaucher disease, type 2 diabetes mellitus and obesity
por: Topaloğlu, Ömercan, et al.
Publicado: (2023) -
Use of insulin degludec/aspart after resolution of euglycemic diabetic ketoacidosis associated with dapagliflozin in a female patient with newly diagnosed maturity onset diabetes of the young type 3
por: Ayhan, Ihsan, et al.
Publicado: (2023) -
De Novo BETA-2 adrenergic receptor gene variant associated with obesity
por: Yaman Kalender, Derya Sema, et al.
Publicado: (2023) -
Beneficial outcomes of glucagon like peptide-1 agonist therapy in a patient with Bardet Biedl syndrome and kidney transplant
por: Erturk, Banu, et al.
Publicado: (2023) -
A rare reason for hospital admission with muscle weakness in the Covid-19 rra: CPT-2 deficiency
por: Akçay, Seçkin, et al.
Publicado: (2023)